Kodiak Sciences Inc (KOD) Share Price Today, Stock Analysis, Annual Report | Value Research Kodiak Sciences Inc (KOD) - Get live share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial report.
  • Price Change
  • Market Capitalisation market-capitalisation-info $126 Mln

  • 12 Month Earnings monthly-earning $-298 Mln
  • Price to Earnings price-to-earning --

Kodiak Sciences Inc (KOD) Share Price

$1.84

As on 28-Sep-2023 16:00 EDT

up-down-arrow $-0.12-6.12%

  • Prev Close info

    $1.96

  • Day's Openinfo

    $1.97

  • Today's Highinfo

    $1.97

  • Today's Lowinfo

    $1.82

  • Today's Volumeinfo

    388,116

Please wait...

Kodiak Sciences Inc (KOD) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Kodiak Sciences (KOD)
-74.30 -22.36 -72.78 -75.82 -68.40 -- --
S&P BSE Sensex*
8.20 1.28 2.99 16.31 20.12 12.69 12.81
S&P Small-Cap 600#
-0.98 -4.98 -4.11 4.69 10.13 1.54 6.57
As on 28-Sep-2023  |  *As on 29-Sep-2023  |  #As on 29-Sep-2023
2022
2021
2020
2019
Kodiak Sciences (KOD)
-91.55 -42.29 104.18 913.38
S&P Small-Cap 600
-17.42 25.27 9.57 20.86
S&P BSE Sensex
4.44 21.99 15.75 14.38

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Kodiak Sciences Inc (KOD) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Kodiak Sciences Inc (KOD)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Co-Founder, Chairman, CEO & Pres

        Dr. Victor Perlroth M.D.

        Sr. VP, CFO & Sec.

        Mr. John A. Borgeson CPA, M.B.A., MBA, CPA

        Headquarters

        Palo Alto, CA

        FAQs for Kodiak Sciences Inc (KOD)

        The total asset value of Kodiak Sciences Inc (KOD) stood at $ 664 Mln as on 30-Jun-23

        The share price of Kodiak Sciences Inc (KOD) is $1.840000 (NASDAQ) as of 28-Sep-2023 16:00 EDT. Kodiak Sciences Inc (KOD) has given a return of -68.4% in the last 3 years.

        Kodiak Sciences Inc (KOD) has a market capitalisation of $ 126 Mln as on 22-Sep-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Kodiak Sciences Inc (KOD) is 0.80 times as on 22-Sep-2023, a -0.69% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Kodiak Sciences Inc (KOD) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Kodiak Sciences Inc (KOD) and enter the required number of quantities and click on buy to purchase the shares of Kodiak Sciences Inc (KOD).

        Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

        The CEO & director of Dr. Victor Perlroth M.D.. is Kodiak Sciences Inc (KOD), and CFO & Sr. VP is Mr. John A. Borgeson CPA, M.B.A., MBA, CPA.

        The promoters of Kodiak Sciences Inc (KOD) have pledged 0% of the total equity as on Jun-23.

        Kodiak Sciences Inc (KOD) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Kodiak Sciences Inc (KOD) was $-298 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $125.89 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-298.45 Mln
        • Cash date-information $378.67 Mln
        • Total Debt info $84.79 Mln
        • Insider's Holding 5.71%
        • Liquidity liquidity High
        • 52 Week range week-range $1.82 - 9.79
        • Shares outstanding share-outstanding 52,453,200
        • 7 Years Aggregate:

          CFO: $-574.04 Mln

          EBITDA: $-854.72 Mln

          Net Profit: $339,217.91 Mln

        About The Company

        • IPO Date 04-Oct-2018
        • Co-Founder, Chairman, CEO & Pres Dr. Victor Perlroth M.D.
        • Sr. VP, CFO & Sec. Mr. John A. Borgeson CPA, M.B.A., MBA, CPA
        • Listing key-listing NASDAQ: KOD
        • Country United States
        • Headquarters headquarters Palo Alto, CA
        • Website website https://kodiak.com
        • Business

          Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor...  antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon